Published on
Jul 19, 2025
Dr Sabari on Efficacy of Zidesamtinib in TKI-Pretreated, Advanced, ROS1+ NSCLC
“In all-comers, we saw a 44% ORR, 31 out of 71 patients with a response, including 2 complete responses. What was most interesting is that in those patients who had [received] prior repotrectinib, [we saw an ORR of] 38%.” Joshua K. Sabari, MD, an assistant …
Source:
OncLive
-
Pending
